PHARMARON(300759)2025-03-27 11:00Group 1: Financial Performance Overview - Revenue for 2024 reached 12.276 billion CNY, a year-on-year increase of 6.4% [13] - Net profit attributable to shareholders was 1.793 billion CNY, up 12.0% year-on-year [13] - Non-IFRS adjusted net profit was 1.607 billion CNY, a decrease of 15.6% compared to the previous year [13] Group 2: Revenue Composition - Revenue from China delivery business accounted for 87%, while overseas delivery business made up 13% [16] - Laboratory services contributed 57% to total revenue, with small molecule CDMO at 24% and clinical research services at 15% [16] - Revenue from North American clients grew by 6.1%, while European clients saw a 23.2% increase; however, revenue from Chinese clients declined by 6.5% [17] Group 3: Client and Project Highlights - The top 20 pharmaceutical companies contributed to a revenue growth of 26.9% [19] - The company participated in 781 drug discovery projects, with 1,062 ongoing clinical research services [30][33] - New signed orders increased by over 20% year-on-year, indicating a positive trend in the biopharmaceutical industry [13] Group 4: Future Outlook and Strategy - The company aims for a revenue growth of 10-15% by 2025 [46] - It will continue to focus on a "full-process, integrated, international, and multi-therapy" strategy to enhance R&D and production efficiency [46] - The company is committed to sustainable development, achieving an AA rating in MSCI ESG ratings for 2024 [22]